The process for developing new drug and biologic products is extraordinarily expensive and time-consuming. Although large pharmaceutical companies may be able to afford the cost of development because they can expect a large return on investment, organizations developing drugs to treat rare and neglected diseases are unable to rely on such returns.
On June 23, 2008, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held a public workshop, "Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies," which sought to explore new and innovative strategies for developing drugs for rare and neglected diseases.
Table of Contents
|1 Introduction and Overview||1-6|
|2 Current Model for Financing Drug Development: From Concept Through Approval||7-11|
|3 The Food and Drug Administration's Orphan Drug Program||12-18|
|4 Diverse Funding Models||19-41|
|5 Strategies for Facilitating Sharing of Research Materials and Data||42-54|
|6 Strategies for Navigating Intellectual Property||55-81|
|7 Strategies for Facilitating Clinical Trials||82-97|
|Appendix A: Agenda||106-112|
|Appendix B: Speaker Biographies||113-127|
|Appendix C: Resources||128-132|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary...